Servier Highlights Novel Approaches to Treating Cancer at the ASCO and EHA 2021 Annual Meetings
News
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Cholangiocarcinoma
Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology Business
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Taiho Oncology and Servier To Present Data on LONSURF® (trifluridine and tipiracil) at 2021 ASCO Gastrointestinal Cancers Symposium (ASCO GI)
Servier Announces a Collaboration to Explore Immune Checkpoint Signaling in Cancer
Servier to Acquire Agios Pharmaceuticals’ Oncology Business
Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer